Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S (ASND) is a healthcare company (biotechnology) based in Denmark. The share price is $266.65, down 1.87% on the day, which values the company at $17.49B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.
Key facts
- Share price
- $266.65−1.87% today
- Market value
- $17.49B
- P/E ratio
- 17.5×last 12 months
- Forward P/E
- 22.0×
- Funk Score
- 55/100
- 200-week average
- $160.8566% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Ascendis Pharma A/S in more detail
ASND trades at 17.5× its last twelve months' earnings, 22.0× next year's expected earnings, 14.5× sales. It sits 66% above its 200-week average of $160.85.
Its Funk Score is 55 out of 100 (financial strength 3.8, profitability 2.6, growth 10.0, each out of 10).
In its favour: Operating margin is expanding. Worth checking: Share count keeps rising; Thin interest cover.
2 of the superinvestors tracked here hold ASND, including Peter Kolchinsky (23.8% of the portfolio), Polen Capital team (0.1% of the portfolio).
Superinvestors holding ASND
2 of the investors tracked here report a position in their latest 13F filing.
- Peter Kolchinsky RA Capital Management23.8% of portfolio · $2.7B · Q2 2026
- Polen Capital team Polen Capital Management0.05% of portfolio · $5M · new · Q3 2026
Health Care companies of similar size
- Alnylam PharmaceuticalsALNY
- Zimmer Biomet HoldingsZBH
- Medpace HoldingsMEDP
- RevvityRVTY
- ExelixisEXEL
- Charles River Laboratories InternationalCRL
- Neurocrine BiosciencesNBIX
- ICONICLR
- Jazz PharmaceuticalsJAZZ
- SolventumSOLV
- BridgeBio PharmaBBIO
- Summit TherapeuticsSMMT
Side by side:ASND vs NBIX (Ascendis Pharma A/S vs Neurocrine Biosciences)ASND vs CRL (Ascendis Pharma A/S vs Charles River Laboratories International)ASND vs EXEL (Ascendis Pharma A/S vs Exelixis)ASND vs ICLR (Ascendis Pharma A/S vs ICON)ASND vs RVTY (Ascendis Pharma A/S vs Revvity)
All health care companies by market valueLargest companies in DenmarkAll stocks A–Z
Ascendis Pharma A/S (ASND): questions and answers
What is ASND's P/E ratio?
Ascendis Pharma A/S trades at 17.5× its last twelve months' earnings and 22.0× next year's expected earnings.
What is Ascendis Pharma A/S's market cap?
Ascendis Pharma A/S is valued at $17.49B at a share price of $266.65.
Is ASND above its 200-week moving average?
Yes. ASND is 65.8% above its 200-week average of $160.85. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Ascendis Pharma A/S growing?
Over the last three fiscal years Ascendis Pharma A/S's revenue grew 141.4% a year.
Does ASND pay a dividend?
Ascendis Pharma A/S does not currently pay a regular dividend.
Which famous investors own ASND?
In their latest quarterly filings, Peter Kolchinsky (23.8% of the portfolio), Polen Capital team (0.1% of the portfolio) hold ASND. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Ascendis Pharma A/S (ASND) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ASND
Underlying data: Yahoo Finance; company filings with the SEC.